[1] Paller AS et al. Prevalence of type 2 inflammatory diseases in pediatric patients with atopic dermatitis: Real-world evidence. AS. J Am Acad Dermatol. 2022;86(4):758-765. DOI: 10.1016/j.jaad.2021.10.038
[2] Paller AS et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trialJ Am Acad Dermatol. 2020;83(5):1282-1293. DOI: 10.1016/j.jaad.2020.06.054
[3] Simpson EL et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156(1):44-56. DOI:10.1001/jamadermatol.2019.3336
[4] Blauvelt A et al. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE) Am J Clin Dermatol. 2022;23(3):365-383. DOI: 10.1007/s40257-022-00683-2
[5] Paller AS et al. A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. Eur Acad Dermatol Venereol. 2021;35(2):464-475. DOI: 10.1111/jdv.16928